XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Net revenues (Tables)
 9 Months Ended
Sep. 29, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of revenue by major customers by reporting segments
The following table disaggregates revenue by global product category for the three and nine months ended September 29, 2024 and October 1, 2023.
Three Months EndedNine Months Ended
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Vascular access$180,896 $169,919 $543,355 $521,356 
Interventional
149,865 134,089 425,687 375,766 
Anesthesia101,154 97,612 299,997 291,786 
Surgical111,746 112,805 328,574 317,781 
Interventional urology83,395 73,622 246,241 226,819 
OEM82,558 82,309 259,080 243,434 
Other (1)
54,761 76,033 148,981 223,638 
Net revenues (2)
$764,375 $746,389 $2,251,915 $2,200,580 
(1)    Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products) and sales pursuant to the manufacturing and supply transition agreement related to our Respiratory business divestiture. For the nine months ended September 29, 2024, amounts reflect the impact from increases in our reserves related to the Italian payback measure pertaining to prior years discussed in Note 13.
(2)    The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally.
Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.